Omnitida BioActive Pen Kit
Disposable pre-filled pens with four once-weekly doses of 0.5 mL each, in 2.5, 5, 10 and 15 mg strengths. Needles and alcohol wipes are included in the kit.
For healthcare professionals and trade partners. Prescription-only medicine. Information on this page is not intended for the general public.
About the product
Omnitida BioActive is a prescription medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist, for once-weekly subcutaneous injection. It is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, and for chronic weight management in adults with obesity, or with overweight and a weight-related comorbidity.
The range includes ready-to-use pre-filled pens with four weekly doses in 2.5, 5, 10 and 15 mg strengths, and 2 mL vials for administration by medical staff in 2.5, 7.5 and 15 mg per 0.5 mL strengths.
Omnitida 2.5 BioActive
2.5 mg / 0.5 mL · 4 dosesWeeks 1–4 · starting dose View details
Omnitida 5 BioActive
5 mg / 0.5 mL · 4 dosesWeeks 5–8 View details
Omnitida 10 BioActive
10 mg / 0.5 mL · 4 dosesWeeks 13–16 View details
Omnitida 15 BioActive
15 mg / 0.5 mL · 4 dosesWeeks 21+ · maximum dose View details
Ingredients & Key Facts
Active ingredient: Tirzepatide
Omnitida contains tirzepatide, a 39-amino-acid modified peptide with a C20 fatty diacid moiety. Binding to albumin prolongs the half-life to about 5 days, allowing once-weekly dosing.
It acts to:
- Enhance first- and second-phase insulin secretion in a glucose-dependent manner
- Reduce glucagon levels in a glucose-dependent manner
- Delay gastric emptying
Flexible dosing regimen
Stepwise titration to improve tolerability:
- Start: 2.5 mg once weekly for 4 weeks (initiation, not for glycaemic control)
- Titration: +2.5 mg after at least 4 weeks on the current dose
- Maintenance dose: 5, 10 or 15 mg once weekly, as prescribed
- Maximum dose: 15 mg once weekly
- Subcutaneous: abdomen, thigh or upper arm; any time of day, with or without meals
Dual-receptor action
Tirzepatide selectively binds to and activates both GIP and GLP-1 receptors — the targets of the native incretin hormones.
Indicated for:
- Glycaemic control in adults with type 2 diabetes, as an adjunct to diet and exercise
- Chronic weight management in adults with BMI ≥ 30 kg/m², or ≥ 27 kg/m² with a weight-related comorbidity
What’s in the box
Each pack includes:
- Pre-filled pen: 1 pen with 4 doses of 2.5 / 5 / 10 / 15 mg, 4 needles (one per dose), alcohol wipes, package leaflet
Pen or vial?
| Attribute | Pre-filled pen | Vial |
|---|---|---|
| Who administers | Patient, at home under physician supervision | Medical staff |
| Doses per unit | 4 fixed doses of 0.5 mL | 2 mL; dose drawn with a syringe |
| Strengths | 2.5 · 5 · 10 · 15 mg | 2.5 · 7.5 · 15 mg |
| In the box | Pen, 4 needles (one per dose), alcohol wipes, leaflet | Vial, leaflet — syringes not included |
| Dose preparation | Prime the new pen, dial the dose | Draw with a U-100 insulin syringe |
Frequently asked questions
What is Omnitida BioActive?
Omnitida BioActive is tirzepatide, a GIP and GLP-1 receptor agonist for once-weekly subcutaneous injection. It is supplied as a pre-filled pen (2.5, 5, 10 and 15 mg per dose) and as a vial (2.5, 7.5 and 15 mg per 0.5 mL). It is a prescription-only medicine.
What is Omnitida BioActive used for?
As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, and for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity.
What are the possible side effects?
The most common side effects are nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain. Warnings include pancreatitis, hypoglycaemia with insulin or sulfonylureas, hypersensitivity reactions, renal impairment with severe GI reactions, diabetic retinopathy and cholelithiasis. See the package leaflet.
What does the pen kit include?
One pre-filled pen with 4 once-weekly doses, 4 needles (one per dose), alcohol wipes and the package leaflet. Vials are supplied with the package leaflet only; syringes are not included.
How does Omnitida BioActive work?
Tirzepatide activates both GIP and GLP-1 receptors. It enhances first- and second-phase insulin secretion and reduces glucagon levels, both in a glucose-dependent manner, and delays gastric emptying.
Who should not use Omnitida BioActive?
It is contraindicated in patients with hypersensitivity to tirzepatide or any component, and with a personal or family history of medullary thyroid carcinoma or MEN 2. It has not been studied in patients with a history of pancreatitis, is not indicated in type 1 diabetes and is not established below 18 years of age.
How is Omnitida BioActive administered?
Once weekly by subcutaneous injection in the abdomen, thigh or upper arm, at any time of day, with or without meals. Rotate injection sites with each dose. With insulin, give separate injections and never mix them.
What if a dose is missed?
Give it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and give the next dose on the usual day. The weekly day can be changed if at least 3 days (72 hours) separate two doses.
How should Omnitida BioActive be stored?
In a refrigerator at +2 °C to +8 °C, in the original carton to protect from light. Do not freeze and do not use a product that has been frozen. Keep out of the reach and sight of children.
How is the dose adjusted over time?
Treatment starts at 2.5 mg and is increased in 2.5 mg steps after at least 4 weeks on each dose. The maintenance dose (5, 10 or 15 mg) is chosen by the prescribing physician based on response and tolerability; if a dose is not tolerated, a lower maintenance dose may be considered.
Supplying distributors, pharmacy chains and clinics
Partner price list, documentation and lead times — on request.
Omnitida BioActive is a prescription-only medicine. It must be sold or administered only on the prescription of a registered physician. Always refer to the package leaflet before prescribing. Manufactured by Biotech Laboratorium LTD, London, UK.